In short-term animal models of ischemia, erythropoietin (EPO) signaling through the heterodimeric EPO receptor (EPOR)/β-common receptor (βCR) is believed to elicit tissue protective effects. However, large, randomized, controlled trials demonstrate that targeting a higher hemoglobin level by administering higher doses of EPO, which are more likely to activate the heterodimeric EPOR/βCR, is associated with an increase in adverse cardiovascular events. Thus, inhibition of long-term activation of the βCR may have therapeutic implications. This study aimed to design and evaluate the efficacy of novel computationally designed βCR inhibitory peptides (βIP). These novel βIPs were designed based on a truncated portion of Helix-A from EPO, specifically residues 11-26 (VLERYLLEAKEAEKIT). Seven novel peptides (P1 to P7) were designed. Peptide 7 (P7), VLERYLHEAK-HAEKIT, demonstrated the most robust inhibitory activity. We also report here the ability of P7 to inhibit βCR-induced nitric oxide (NO) production and angiogenesis in human umbilical vein endothelial cells (HUVECs). Specifically, we found that P7 βIP completely abolished EPO-induced NO production. The inhibitory effect could be overcome with super physiological doses of EPO, suggesting a competitive inhibition. βCR-induced angiogenesis in HUVEC's was also abolished with treatment of P7 βIP, but P7 βIP did not inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis. In addition, we demonstrate that the novel P7 βIP does not inhibit EPO-induced erythropoiesis with use of peripheral blood mononuclear cells (PBMCs). These results, for the first time, describe a novel, potent βCR peptide inhibitor that inhibit the actions of the βCR without affecting erythropoiesis.
Introduction
Erythropoietin (EPO) and the cytokines human interleukin (IL)-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors are members of the hematopoietin receptor superfamily. These receptors signal through heterodimers of a cytokine-specific alpha chain and the common β chain or the β-common receptor (βCR) [1, 2] . The human βCR is a glycoprotein with an extracellular region composed of 427 amino acids and a 437 amino acid intracellular domain [3] [4] [5] . The ectodomain of the βCR exists as an intertwined homodimer resulting in an arch like structure the overall structure consists of four such domains [4] . The βC-subunits that intertwine are interlocked by swapping of the β-strand of domain 1 of one βC-subunit and domain 3 of the other subunit [1] ; domain 4 is positioned adjacent to the membrane. Although initially the βCR was believed to be only essential for high binding efficiency of the respective cytokines [6] , it is now clear that the βCR is the principal signal transducing subunit and has an important functional role.
Binding of the ligand to its cognate alpha-chain results in recruitment of the βCR to form a heterodimer, which initiates the downstream signaling cascade. The βCR is thought to activate three principle signaling pathways: janus kinase/signal transducer and activator of transcription (JAK/STAT), mitogen-activated protein kinase (MAPK) pathway, and phosphatidylinositol 3-kinase (PI3 K) pathway [7] [8] [9] [10] to regulate a variety of cellular processes including proliferation and differentiation. We have shown that activation of the βCR, occurring with high doses of erythropoietin, can result in induction of nitric oxide (NO) and angiogenesis via vascular endothelial growth factor receptor-2 (VEGFR-2) [11] . Excessive VEGFR-2 activation has been shown to accentuate inflammation [12] and atherosclerosis [12] [13] [14] in animal models. However, EPO has been shown to exert tissue protection in states of ischemia [15] and sepsis [16, 17] , which was suggested to be dependent on the presence of the βCR [17] . These data suggest that although in the short-term activation of the βCR might have tissue protective effects, over the long run activation of the βCR may have adverse cardiovascular effects and may promote cancer metastasis due to the βCR's ability to increase angiogenesis via upregulation of VEGF and its interaction with VEGFR-2 [11] . Upregulation of IL-3 receptor and constitutive phosphorylation of the βCR serine 585 has been demonstrated in patients with acute myeloid leukemia (AML). Further, IL-3 is thought to amplify inflammation in sepsis [18] . These data suggest that inhibition of the βCR could have therapeutic utility to mitigate the side effects withnessed with long term βCR activation on the cardiovascular system, cancer metastasis, and in sepsis.
In the present study, we describe the computational design of a novel βCR inhibitory peptide (βIP), which is a potent and selective inhibitor of the βCR in vitro, and the experimental characterization of the peptide effects on erythropoiesis with use of peripheral blood mononuclear cells (PBMCs). Taken together, this study provides direct evidence that the P7 βIP is a competitive peptide inhibitor of the βCR by inhibiting nitric oxide (NO) and angiogenic potential of the βCR without affecting erythropoiesis.
Materials and methods

Tissue culture and reagents
All tissue culture reagents and human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Basel, Switzerland). Vascular endothelial growth factor (VEGF) was obtained from R&D (Minneapolis, MN). Interleukin (IL)-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) were obtained from PreProtech (Rocky Hill, NJ) and Human recombinant erythropoietin (EPO) from Zydus (Cadila, India). EPO stimulating peptide (ESP), which was derived from a 11-amino acid peptide sequence of the Helix-B of EPO which interacts with the βCR [19] also known as either pHBSP or ARA290, and the βCR inhibitory peptide (βIP) were synthesized by the core facility.
Computational details
Structural alignments were performed on the jCE/jFATCAT Structure Alignment Server V. 2.11.
Free energy calculations were performed using GROMACS [20] with the same protocol that was previously developed by Dahan et al. to design phospholipid (PL) based prodrugs for inflammatory bowel disease drug targets [21] . The proteins and peptides were modeled with the AMBER ff-03 force field and the TIP3P model described water molecules. All calculations were done in a periodical box of water with dimension 60 × 60 × 60 Å. Free energy calculations were done using the Thermodynamic Integration [22, 23] and Umbrella Sampling/ WHAM methods [24] .
Design of novel βCR peptides
Due to the lack of X-ray structures for the βCR/EPO complex, we have used the βCR/GM-CSF interface region from the X-ray structure of the cytokine receptor complex (PDB code: 4NKQ). The jCE/jFATCAT Structure Alignment Server V. 2.11 was used for the sequence alignment (Fig. 1A , top) and structural overlay (Fig. 1A , bottom left) between a mutant EPO (PDB code:1EER, chain A), which the glycosylation site asparagine residues have been replaced with lysine, [25] and GM-CSF (PDB code: 4NKQ, Chain C) [26] in complex with βCR. We found that Helix-A in EPO aligns well with helix-A in GM-CSF that binds strongly to βCR. From the x-ray structure of GM-CSF bound to βCR (both 2GMF.pdb and 3CXE.pdb), it is clear to see that helix-A of GM-CSF interacts with βCR. In particular, the βCR residues Y39, Y365 and Y421 (in the D1/D5/D6 elbow region) interact strongly with helix-A of GM-CSF, which is the basis for the alignment we used here. Additionally, E21 has been identified as a critical residue on GM-CSF. By mutating E21, GM-CSF turns into an antagonist of the βCR [3] . Based on this structural analysis, we extracted a portion of Helix-A from EPO consisting of 16-amino acids (VLERYLLEAKEAEKIT) starting from residues 11-26 as a template to design seven novel βIPs. We introduced single and double point mutants to the 16-amino acids peptides from EPO and calculated free energy changes associated with the mutations. Computational models of the protein and peptides were prepared using the GROMACS software package [20] and the procedure is explained in detail elsewhere [21] .
The Free Energy Perturbation (FEP) [27] calculations using the Thermodynamic Integration (TI) method [22, 28] were used to compute the difference in free energy (ΔΔG) between the wild-type and mutant states, where negative (ΔΔG) values indicate the increase in binding affinity of the peptide to the protein (βCR). This value is a combination of the peptide states, both in the solvent (water box) as well as bound to the protein (βCR) environments.
To save computational cost, we used a truncated model of βCR that consists of 105 residues (from H331 to T436) and a truncated part of Helix-A from EPO, which include a portion of the low affinity binding site (site 2) for the EPOR, with 16-amino acids (VLERYLLEAKEAEKIT) from residues 11-26 to perform the FEP-TI calculations. We introduced several charged, polar, hydrophobic and hydrophilic amino acids to replace Leucine (L) at site-7 and found that the singly protonated Histidine (at the delta nitrogen atom) (L7H) establishes a strong π-π stacking interaction with the singly protonated H367 (at the Nδ atom) in βCR, which, in turn, enhanced the binding affinity of the peptide (ΔΔG = −1.08 ( ± 0.19) kcal mol −1 ) to the protein. Therefore, we chose the optimized VLERYLHEAKEAEKIT peptide model as the starting structure to introduce double mutants and we built seven βIP models with different amino acid combinations at sites 7 and 11 involving residues E, H, Y and N (Fig. 1B) . We found that substitution of Glutamic acid (E) with Histidine (H, singly protonated at the Nδ atom) at site 11 (E11H) formed an edge-to-π interaction with Y365 and H367 residues in βCR ( 
Assay of nitric oxide production
Bioavailable NO was determined as previously described [11] . Briefly, after treatment with EPO alone or in combination with the novel βIP (1 mM or 10 μM) for 3 h, human umbilical vein endothelial cells (HUVECs) were incubated with 5 μM 4-amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM) diacetate (Invitrogen, Waltham, MA) for 30 min at 37°C in the dark. Excess extracellular probe was removed by washing in Hanks balanced salt solution followed by incubation for 10 min at room temperature to allow for probe de-esterification. DAF-FM fluorescence increases by approximately 160-fold when it reacts with NO. Green fluorescence was measured using an inverted microscope Axiovert 200 (Carl Zeiss, Jena, Germany) equipped with CCD camera and image acquisition/analysis software AxioVision (Version 4.5). Images were acquired every 1-min for at least 20 min, and fluorescence intensity was measured in 20-30 cells per field in at least 6 fields per experiment.
Angiogenesis assay
To demonstrate the effectiveness of βIP to inhibit angiogenesis of endothelial cells, we analyzed tube formation with respective treatments alone or in combination with the novel βIP (1 mM). Briefly, HUVECs were plated on a 48-well tissue culture plate pre-coated with 250 μL of Cultrex Basement Membrane Extract (Trevigen, Gaithersburg, MD) in 300 μL endothelial basal medium-2 supplemented with 1% fetal bovine serum with or without treatment(s) of VEGF (100 ng/mL or 52.6 nM), EPO (50 mIU/mL or 11.45 fM; Conversion was calculated by 1IU = 8 ng = 0.229 pM) ESP (25 ng/mL or 20 nM), IL-3 (25 ng/mL or 1.7 nM), IL-5 (25 ng/mL or 1 nM), or GM-CSF (25 ng/mL or 1.8 nM). After 20 h of incubation in a 5% CO 2 humidified atmosphere at 37°C, the 3-dimensional structures formed by the cells in this matrix were examined using an inverted phase-contrast microscope. Tube-like structures were quantified by measuring the sum of the lengths of all tubules per field using the image analysis software AxioVision, Version 4.5. Three randomly selected low-power fields were examined for each sample.
PBMC cell culture and erythroid expansion
To demonstrate whether βIP had an effect on erythropoiesis, we analyzed erythroid expansion with and without the novel βIP (1 mM). Peripheral blood mononuclear cells (PBMCs) from a healthy adult donor were purchased from StemCell Technologies (Vancouver, Canada). PBMC were seeded at a density of 0.5 × 10 6 cells/ml in StemSpan SFEM II medium (StemCell Technologies) supplemented with or without StemSpan Erythroid Expansion Supplement (StemCell Technologies) and 1% (vol/vol) P/S. Cells were cultured for 8 days at 37°C in 5% CO2 incubator with the media being changed every two days [29] .PBMCs are treated with peptide inhibitor (25 μM) from Day 2.
RNA extraction and gene expression analysis
Hemoglobin β (HBB), transferrin receptor (CD71), and glycophorin A (GYPA) mRNA level were assessed using qPCR. Total RNA was extracted from 1 × 10 5 erythroid blast cells using the RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Total RNA (0.5 μg) was reverse transcribed into cDNA using Iscript cDNA synthesis kit (Bio-Rad, Hercules, California) following the manufacturer's instructions. The qPCR was performed with 1 μL cDNA and 1.5 μM of each forward and reverse primer in a 10 μL reaction volume using SYBR green in CFX manager 3.0 (Bio-Rad). Data were normalized to glyceraldehydes 3-phosphate dehydrogenase (GAPDH) mRNA. Primer sequences: GAPDH-F: GAAGGTGAAGGTCGGAGTCA GAPDH-R: GAGGTCAATGAAGGGGTCAT HBB-F: GCACGTGGATCCTGAGAACT HBB-R: GCCACCACTTTCTGATAGGC CD71-F: TCTGCTATGGGACTATTGCTG CD71-R: CTGTTGCAGCCTTACTATACG GYPA-F: GTACCACTGAGGTGGCAATG GYPA-R: AAGGCACGTCTGTGTCAGGT
Statistical and data analysis
One-way ANOVA with tukey's multiple comparison test was used to detect differences in experiments using GraphPad Software version 6.0 (La Jolla, CA). All data are presented as means ± SEM. Significance was defined as P ≤ 0.05.
Results
P7 βCR inhibitory peptide inhibits EPO stimulation of nitric oxide in HUVEC
We have previously demonstrated that in human bone marrow angiogenic cells EPO leads to the stimulation of NO production via the heterodimeric βCR/EPOR [11] , this was confirmed by Su et al. in human endothelial cells [30] . To demonstrate the efficacy of the computationally designed novel βIPs to block the βCR, we tested their ability to block EPO stimulated NO in HUVECs, by quantifying bioavailable NO using DAF-FM. We tested 7 putative βIPs. Although multiple βIPs significantly decreased bioavailable NO production, P7 βIP C.R. Kilar et al.
Peptides 104 (2018) [1] [2] [3] [4] [5] [6] was the most efficacious peptide in decreasing bioavailable NO, thus all subsequent work utilized P7 βIP (Fig. 2) .
The inhibition of the βCR by P7 βCR inhibitory peptide is competitive in nature
The P7 βIP was designed to be specific to the binding site of EPO to the βCR. This would result in competitive inhibition of the βCR. To confirm this, we analyzed whether the inhibition of the βCR by P7 βIP could be overcome with increasing doses of EPO. We found that P7 βIP at 10 μM could be overcome with 5 IU/mL of EPO treatment for 3 h (Fig. 3) .
βCR-induced angiogenesis is blocked with novel P7 βCR inhibitory peptide
We have previously shown that activation of the βCR leads to phosphorylation of VEGFR2, AKT and eNOS, all important mediators of angiogenesis. To examine if P7 βIP could inhibit the angiogenic effects of βCR activation, we examined the ability of P7 βIP to inhibit tube formation induced by EPO and in HUVECs. We found that P7 βIP was able to block tube formation by all hematopoietin signaling cytokines to background levels (Fig. 4) . We have previously shown that VEGFR-2 activity depends on the presence of the βCR. Importantly, the P7 βIP did not affect VEGF-induced tube formation.
Novel P7 βCR inhibitory peptide does not inhibit erythropoiesis
To confirm that the novel P7 βIP did not interfere with the erythropoietic effects of EPO, we examined the effects of P7 βIP on expression of HBB, CD71, and GYPA after treatment with a PBMC -expansion supplement. We found that P7 βIP did not inhibit the ability of EPO to increase expression of HBB, CD71, or GYPA (Fig. 5 ) in erythroidenriched PBMCs. In addition, when we treated the PBMC for 7 days with P7 βIP, there was no increased expression of HBB, CD71, or GYPA (Fig. 5 ).
Discussion
To our knowledge, there are currently no peptide inhibitors of the βCR. P7 βIP was developed in-silico based on the crystal structure of the Helix-A regions of both GM-CSF and EPO to act as a competitive inhibitor of the βCR (Fig. 1) . We demonstrated that the P7 βIP could inhibit EPO mediated NO production (Figs. 2 and 3 ) and endothelial tube formation (Fig. 4) . The P7 βIP also inhibited IL-3, IL-5, and GM-CSF induced tube formation with similar potency. Additionally, we observed that low dose P7 βIP could be overcome with super-physiological doses of EPO (Fig. 3) , suggesting a competitive inhibition. Moreover, we also describe that P7 βIP does not lead to an increase in erythropoiesis nor does it block the erythropoietic effects of EPO (Fig. 5) , suggesting that the novel P7 βIP solely binds to the βCR. Futhermore, P7 βIP did not appear to display signs of cytotoxicity to cells during prolonged treatments, however, further evaluation to the cytotoxicity of the peptide are warranted. Taken together, our results describe a novel, selective inhibitory peptide of the βCR.
Previously, we have demonstrated that the βCR is responsible for EPO-induced production of bioavailable NO [11] . Additionally, we and others have shown that EPO [15, 31] and other βCR signaling cytokines [32, 33] increase angiogenesis through activation of the βCR, although this has been suggested to be cell type dependent [34] , and requires the Fig. 2 . Ability of novel βCR inhibitory peptides to block EPO-stimulated production of bioavailable NO in cultured endothelial cells. HUVECs were treated with the indicated βCR inhibitory peptide (1 mM) for 30-min prior to being incubated with 50 U/mL EPO for 3 h before measuring bioavailable NO with DAF-FM diacetate. All values are means ± SEM; one-way ANOVA followed by tukey's multiple comparison test. *P < 0.05 when compared to control; #P < 0.05 when compared to EPO. Results shown are representative of three independent experiments. Fig. 3 . Inhibition by P7 βIP can be overcome with super-physiological doses of EPO. HUVECs were treated with the P7 βIP (10 μM) for 30-min prior to being incubated with increasing doses of EPO for 3 h before measuring bioavailable NO with DAF-FM diacetate. All values are means ± SEM; one-way ANOVA followed by tukey's multiple comparison test. *P < 0.05 when compared to control; #P < 0.001 when compared to control. $P < 0.01 when compared to EPO (1IU/mL). Results shown are representative of three independent experiments.
presence of vascular endothelial growth factor receptor (VEGFR)-2 [11] . Although the ability of VEGF to increase NO in bone marrow cells required the presence of the βCR, the P7 βIP did not block VEGFinduced angiogenesis. Thus, while VEGFR-2 signaling, in some way, is dependent on the presence or structural integrity of the βCR [11] , the inhibitor does not interfere with this signaling. This is advantageous since VEGFR-2 signaling is critical to endothelial health [35] [36] [37] .
While the P7 βIP was designed to target the binding of EPO to the βCR, it blocked the effects of all ligands known to interact with the βCR. Additionally, there was no effect on erythropoiesis, suggesting that P7 βIP is selective for the βCR and does not interact with the homodimeric EPO receptor. It has been reported that patients receiving elevated doses of EPO to achieve a higher hemoglobin target have an increased incidence of morbidity and mortality from heart disease and stroke [38] [39] [40] . We hypothesize that blockade of the βCR with P7 βIP, in patients receiving elevated doses of EPO may negate the increased morbidity and mortality without altering erythropoiesis by EPO.
In conclusion, to the best of our knowledge, this is the first computational and experimental study to demonstrate the design and characterization of a novel peptide inhibitor of the βCR. This P7 peptide has been shown to be effective in the inhibition of the βCR thus inhibiting downstream actions, such as angiogenesis and bioavailable NO production, without effecting erythropoiesis. These mentioned findings highlight the potential of this peptide as a novel therapeutic to decrease the harmful side effects of EPO therapy in patients undergoing chemotherapy or patients with CKD. In this regard, further tests aimed at evaluating the efficacy of the peptide in vivo are warranted.
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